RxDoctor Payments Data

Owen Qi, MD

Ophthalmology · Munster, INNPI 1548610397

Payments from drug & device makers

$2,449in general payments, 2019–2025

Across 57 payments — averaging $42.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bausch & Lomb, A Division Of Bausch Health US, LLC$505
  • Rxsight Inc$490
  • Bausch & Lomb Americas Inc.$449
  • Alcon$240
  • Sight Sciences, Inc.$204
  • Johnson & Johnson Surgical Vision, Inc.$112
  • plus $449 from 11 others

What the payments were for

  • Food & beverage$2,449100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,449 in reported general payments places this provider in the 60th percentile of 266 ophthalmology providers in Indiana.

See all ophthalmology providers in Indiana

Medicare billing

Part B allowed, 2024
$272,362
Medicare patients
793
Services billed
2,868

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XiidraLifitegrast14$23,910
RestasisCyclosporine17$22,197
LumiganBimatoprost22$14,115
Cyclosporine18$10,877
CombiganBrimonidine Tartrate/Timolol25$9,322
Prednisolone Acetate233$5,234
MoxifloxacinMoxifloxacin Hcl196$4,905
Ketorolac Tromethamine134$2,145
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol16$2,089
Latanoprost273$1,960
Travoprost21$1,618
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat54$1,084
Fluorometholone13$740
Timolol Maleate78$561
Dorzolamide Hcl35$517

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$90$45,63564 claims
Bausch & Lomb Americas Inc.Xiidra$449$23,91014 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 266 ophthalmology providers in Indiana.

Other ophthalmology in Munster

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →